Back to Results
First PageMeta Content
Law / Patent infringement / Patent / Food and Drug Administration / Generic drug / Evergreening / Pharmaceutical sciences / Clinical research / Drug Price Competition and Patent Term Restoration Act


Client Alert April 14, 2015 Federal Circuit Addresses Damages in the Hatch-Waxman Context By Matt D’Amore
Add to Reading List

Document Date: 2015-04-13 20:25:39

Open Document

File Size: 65,41 KB

Share Result on Facebook

Company

Uniloc USA Inc. / Georgia-Pacific / Thys Co. / Marvel Enterprises Inc. / Microsoft Corp. / Morrison & Foerster LLP / Astra / Astrazeneca AB / Apotex Corp. / /

Country

United States / /

Currency

USD / /

/

Event

Patent Filing / /

IndustryTerm

pharmaceutical formulation / multicomponent product / pharmaceutical product / multi-component products / pharmaceutical cases / non-infringing product / commercialized products / generic products / pharmaceutical patent holders / /

Organization

Supreme Court / US Federal Reserve / FDA / United States Court of Appeals / /

/

Position

mofo.com Attorney / Lawyer / /

Product

Prilosec / Omeprazole / /

PublishedMedium

The American Lawyer / /

URL

www.mofo.com / /

SocialTag